Entera Bio Ltd., 2026-08-12
A new SEC Form D private-offering notice from Jerusalem, a $274,999,976 filer-stated offering target in Biotech. The source filing is one click away.
What this filing says
Clinical-stage biopharmaceutical company developing oral tablet delivery of peptide and large-molecule therapeutics via its N-Tab platform, publicly traded on Nasdaq as ENTX.
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.
Other Form D filings from the same week
each with its own page and its own EDGAR source- Abcuro, Inc., 2026-08-13, $176.5M, Newton, MA
- Trace Biosciences Inc., 2026-08-12, $16.2M, Beaverton, OR
- Paterna BioSciences HoldCo Inc., 2026-08-12, $11.2M, Salt Lake City, UT
- Merlin Biotech, Inc., 2026-08-11, $50K, Doylestown, PA
- ELLA LEROY Corp, 2026-08-11, $75K, Honolulu, HI
- Grace Therapeutics, Inc., 2026-08-11, $10M, Princeton, NJ
The Monday digest, free
A summary of who raised money last week: the ones worth a call first, then every company that filed, by state and sector. One email, Monday mornings. No spam, unsubscribe anytime.
By subscribing you agree to our Terms and Privacy Policy.